Allspring Global Investments Holdings LLC Sells 391,487 Shares of Enovis Co. (NYSE:ENOV)

Allspring Global Investments Holdings LLC lowered its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 57.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 293,317 shares of the company's stock after selling 391,487 shares during the period. Allspring Global Investments Holdings LLC owned about 0.52% of Enovis worth $12,994,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ENOV. UMB Bank n.a. lifted its position in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after purchasing an additional 437 shares during the period. Pinnacle Bancorp Inc. lifted its position in shares of Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after purchasing an additional 300 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in shares of Enovis in the 3rd quarter worth about $55,000. FMR LLC lifted its position in shares of Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after purchasing an additional 484 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Enovis in the 3rd quarter worth about $217,000. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Stock Down 2.6 %

Shares of Enovis stock traded down $1.14 during trading on Friday, hitting $42.77. The company's stock had a trading volume of 458,733 shares, compared to its average volume of 963,719. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The company has a fifty day simple moving average of $45.08 and a two-hundred day simple moving average of $44.33. The company has a market capitalization of $2.43 billion, a PE ratio of -19.53 and a beta of 1.94. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Enovis has an average rating of "Moderate Buy" and an average price target of $64.83.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.